Lefamulin Rivals Moxifloxacin in Treating Community-Acquired Bacterial Pneumonia: Evidence from a Randomized Trial
Abstract
Background: Lefamulin is a new pleuromutilin antibiotic that demonstrates effectiveness comparable to moxifloxacin in treating community-acquired bacterial pneumonia (CABP). It targets various pathogens, and can be administered both orally and intravenously. Our prospective randomized clinical trial aimed to assess the clinical effectiveness and tolerability of Lefamulin (150 mg IV every 12 hours) versus Moxifloxacin (400 mg daily) in patients with CABP classified as PSI class III or higher.Materials and methods: This study investigated 150 adult bacterial CABP patients divided into two groups. Compared intravenous Lefamulin (150mg every 12h) to oral (600mg every 12h, for 5 days) against intravenous moxifloxacin (400mg every 24h) to oral (400mg every 24h, for 7 days). Patients' PSI and CURB-65 scores were determined, and causal organisms identified. Effectiveness and safety were assessed via follow-ups at weeks 2 and 4, focusing on PSI risk classes II-IV and CURB-65.Results: Preliminary results showed that the two study groups were similar in demographic and baseline characteristics, such as systemic inflammation, and a similar distribution of bacterial pathogens. The results also showed a comparable clinical response profile between the two groups after the two treatment periods. Patients in both groups were not free of clinical complications and adverse effects, albeit at slightly varying rates.Conclusion: This research concluded that lefamulin is non-inferior to…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.